Kura Oncology Inc (KURA)
10.80
+0.74
(+7.36%)
USD |
NASDAQ |
Nov 22, 16:00
10.80
0.00 (0.00%)
After-Hours: 20:00
Kura Oncology Cash from Financing (Quarterly): 2.202M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 2.202M |
| June 30, 2024 | 3.04M |
| March 31, 2024 | 148.37M |
| December 31, 2023 | 0.691M |
| September 30, 2023 | 0.084M |
| June 30, 2023 | 94.01M |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 34.71M |
| September 30, 2022 | 0.88M |
| June 30, 2022 | 2.669M |
| March 31, 2022 | 0.303M |
| December 31, 2021 | 0.794M |
| September 30, 2021 | 2.258M |
| June 30, 2021 | -6.566M |
| March 31, 2021 | 0.079M |
| December 31, 2020 | 327.04M |
| September 30, 2020 | 4.683M |
| June 30, 2020 | 137.37M |
| March 31, 2020 | 0.247M |
| December 31, 2019 | 0.583M |
| Date | Value |
|---|---|
| September 30, 2019 | 0.559M |
| June 30, 2019 | 109.86M |
| March 31, 2019 | 0.102M |
| December 31, 2018 | 1.144M |
| September 30, 2018 | 73.97M |
| June 30, 2018 | -0.125M |
| March 31, 2018 | 57.65M |
| December 31, 2017 | -0.338M |
| September 30, 2017 | 53.71M |
| June 30, 2017 | 0.189M |
| March 31, 2017 | 0.005M |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 7.453M |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 50.28M |
| September 30, 2015 | -0.252M |
| June 30, 2015 | -3.739M |
| March 31, 2015 | 56.58M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-6.566M
Minimum
Jun 2021
327.04M
Maximum
Dec 2020
37.67M
Average
1.541M
Median
Cash from Financing (Quarterly) Benchmarks
| Halozyme Therapeutics Inc | 18.56M |
| AIM ImmunoTech Inc | 0.137M |
| Perspective Therapeutics Inc | 0.628M |
| Protalix BioTherapeutics Inc | -20.42M |
| Armata Pharmaceuticals Inc | -0.061M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -43.44M |
| Cash from Investing (Quarterly) | 45.54M |
| Free Cash Flow | -169.24M |
| Free Cash Flow Per Share (Quarterly) | -0.4996 |
| Free Cash Flow Yield | -18.72% |